Fig. 6: Prediction of EGFR-TKI sensitivity for NSCLC patients with EGFR-activating mutations by using the HX103-based FACS approach. | Nature Communications

Fig. 6: Prediction of EGFR-TKI sensitivity for NSCLC patients with EGFR-activating mutations by using the HX103-based FACS approach.

From: A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

Fig. 6

a Study design and patient allocation. The collected biopsy samples (n = 31) from NSCLC patients were divided into two groups according to EGFR mutation status, followed by the analysis of HX103-based FACS. Fifteen patients received EGFR-TKIs and therapy responses to EGFR-TKI were examined by CT imaging. b Waterfall plot for best percentage change in target lesion size (red), the labeling for EGFR(+) (gray) and EGFR(+)HX103(+) (blue) are shown for NSCLC patients carrying EGFR-activating mutations who received EGFR-TKIs (n = 15). c Analysis of the prediction for EGFR-activating mutations by the percentage of EGFR(+)HX103(+) in 31 biopsy samples from NSCLC patients. d Box plots of EGFR(+)HX103(+), EGFR(+) and HX103(+) in biopsy samples with EGFR-activating mutations and wild-type. The line in the box corresponds to the median. The boxes go from the upper to the lower quartiles of the data. Whiskers represent Min to Max, shown with all data points. For EGFR-activating mutation, n = 15; for EGFR wild-type, n = 16. Statistics was performed using Mann–Whitney test (two-sided). e Comparison of responsiveness to EGFR-TKI therapy with the percentage of EGFR(+)HX103(+) in 15 NSCLC patients carrying EGFR-activating mutations. Of note, the therapy responses of two patients (9 and 12) were evaluated. f Box plots of the percentage of EGFR(+)HX103(+), EGFR(+), or HX103(+) with responsiveness to EGFR-TKI. CR or PR cases were categorized as responders, and SD or PD cases, as non-responders. The line in the box corresponds to the median. The boxes go from the upper to the lower quartiles of the data. Whiskers represent Min to Max, shown with all data points. For CR/PR, n = 9; for SD/PD, n = 4. Statistics was performed using Mann–Whitney test (two-sided). g, h Representative CT scans comparisons of pre-TKI and post-TKI treatment showed the change in the size of tumor from NSCLC patients with EGFR-activating mutations, as well as the corresponding labeling parameters of EGFR(+)HX103(+) (blue), HX103(+) (orange) and EGFR(+) (gray). Source data are provided as a Source Data file.

Back to article page